Résumé
The original article by Rimmer et al.1 in this month’s issue reports on how patients with lower-grade glioma (LrGG) experience life and how LrGG affects their quality of life (QoL). The authors conducted semi-structured interviews to obtain a comprehensive understanding of the primary QoL determinants in 28 patients with LrGG. They found that patients experience a wide range of symptoms and impairments with a clear impact on their daily life. Yet, this impact might not be fully captured by the classically used QoL questionnaires.The neuro-oncology community recognizes the crucial importance of preserving QoL in patients with LrGG due to their relatively young age, high psychological distress, frequent cognitive impairment,2 and reduced life expectancy. This guides therapeutic decision-making to balance the treatment-related effect on survival and potential short- or long-term consequences on neurocognition and QoL. New composite endpoints, including the preservation of QoL and/or neurocognition, have been proposed and tested in cohort studies (eg, survival with a Karnofsky performance status [KPS] score ≥803) and prospective clinical trials (eg, survival without neurocognitive deterioration, NCT02444000 and NCT04702581 trials; qualified overall survival, NCT05331521 trial).